Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
90Y-NRT6020
- Development stage
- Unknown
- Lead developer
- Chengdu Newray Medical Technology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
90Y-NRT6020 is a Class I therapeutic radiopharmaceutical developed by Chengdu New Radiomedicine Technology (NRT). It is a radioligand therapy (RLT) consisting of a small-molecule fibroblast activation protein inhibitor (FAPI) ligand conjugated to the high-energy beta-emitting radioisotope yttrium-90 (90Y). The drug specifically targets fibroblast activation protein (FAP), which is highly overexpressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment of over 90% of epithelial-derived solid tumors. Upon binding to FAP, 90Y-NRT6020 delivers localized, high-energy beta radiation to destroy tumor cells and disrupt the supportive tumor stroma while minimizing damage to surrounding healthy tissues. It is currently in Phase I clinical development in China for the treatment of FAP-positive advanced malignant solid tumors.
- Other names
- 90Y-NRT6020 Injectionyttrium Y 90 NRT6020
02
Targets
DNAFAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 90Y-NRT6020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 90Y-NRT6020.